Table 2 Mean total number of drug prescriptions per GP per year, standardised per 1000 enlisted patients for the randomised more intensively involved group in the intervention region versus a matched control group
|  | Desired direction of drug | pre | Short term | Δ short term | Long term | Δ Long term | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | I (n = 27) | C (n = 26) | I (n = 27) | C (n = 23) | I (n = 27) | C (n = 26) | I (n = 27) | C (n = 26) | I (n = 27) | C (n = 26) |
Drug indicators | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Antibiotics2 | ↓ | 611 (536,833) | 530 (421,665) | 643 (413,812) | 524 (443,622) | 6 (-43,82) | 3 (-48,38) | 661 (435–734) | 526 (418,649) | 11 (-92,73) | -7 (-61,47) |
Chinolones2 | ↓↓ | 34 (18,51) | 25 (14,36) | 27 (12,47) | 24 (12,32) | 3 (-12,8) | -2 (-8,2) | 30 (21,38) | 19 (17,33) | -3 (-11,3) | -1 (-7,5) |
Nitrofurantoin1 | ↑ | 23 (15,31) | 31 (21,40) | 27 (20,35) | 31 (21,42) | 4 (-3,12) | 1 (-3,5) | 32 (24,41) | 36 (26,46) | 9 (1,18) | 6 (0,11) |
Trimethoprim1 | ↑ | 32 (22,41) | 29 (19,38) | 32 (20,44) | 28 (20,37) | 1 (-6,7) | 0 (-4,3) | 26 (18,35) | 23 (16,31) | -5 (-13,3) | -5 (-11,0) |
Amoxicillin with clav.acid2 | ↓ | 33 (22,68) | 28 (16,43) | 41 (16,67) | 26 (17,45) | 5 (-9,19) | -2 (-8,5) | 23 (16,64) | 30 (21,37) | -3 (-16,10) | 3 (-8,10) |
Amoxicillin1 | ↓ | 92 (59,125) | 104 (63,145) | 57 (37,76) | 98 (62,135) | -36 (-75,4) | -5 (-16,6) | 78 (37,119) | 96 (65,128) | -14 (-36,8) | -7 (-25,10) |
Doxycyclin1 | ↓ | 125 (89,160) | 89 (73,105) | 113 (82,144) | 86 (71,100) | -12 (-37,14) | -4 (-12,5) | 103 (74,132) | 81 (69,93) | -22 (-52,8) | -8 (-16,0) |
Mupirocin1 | ↓ | 12 (5,20) | 7 (4,9) | 10 (3,16) | 6 (3,9) | -3 (-5,0) | -1 (-3,2) | 8 (4,12) | 6 (3,8) | -5 (-9,0) | -1 (-3,1) |
Cholesterol synthesis inhibitors (Statins) 1 | ↑↑ | 150 (119,182) | 139 (109,170) | 182 (144,220) | 166 (129,203) | 32 (20,43) | 27 (17,36) | 229 (185,273) | 194 (153,235) | 79 (60,98) | 55 (35,75) |
Asthma & COPD | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Long-term beta2-sympaticomimetics1 | ↑ | 35 (27,44) | 36 (28,43) | 34 (25,42) | 33 (25,41) | -2 (-5,2) | -2 (-7,2) | 32 (23,42) | 28 (21,35) | -3 (-8,3) | -8 (-14, -2) |
Asthma | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Short-term beta2-sympaticomimetics1 | ↓ | 37 (26,48) | 35 (23,47) | 37 (26,48) | 37 (25,49) | 0 (-4,4) | 2 (-1,6) | 34 (24,44) | 36 (24,48) | -3 (-8,2) | 1 (-4,6) |
Inhaled corticosteroids2 | ↑ | 24 (16,35) | 24 (13,28) | 22 (12,32) | 21 (12,33) | -5 (-8,0) | -1 (-5,5) | 15 (10,29) | 19 (13,28) | -9 (-11, -4) | 1 (-7,1)* |
COPD | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Short-term beta2-sympaticomimetics1 | - | 65 (51,79) | 38 (29,47) | 63 (48,79) | 39 (29,48) | -2 (-9,6) | 1 (-4,5) | 61 (45,77) | 32 (25,40) | -4 (-12,5) | -5 (-12,1) |
Inhaled corticosteroids1 | ↓ | 59 (45,74) | 48 (37,59) | 55 (40,70) | 46 (34,60) | -5 (-10,1) | -2 (-7,3) | 41 (29,53) | 39 (28,50) | -18 (-26, -11) | -9 (-16, -2) |